Modus Therapeutics Holding AB

Welcome to today's live interview with Modus Therapeutics. I'm joined by the company's CEO, John Öde, as usual. John, you have published your Q1 report here this morning. I thought you would briefly give your view on the work during the first quarter and what you see as the highlights during the period.

Thank you, Martin. I think it has been very intensive. We have made very clear progress that makes us say that we are on track with the study that we are conducting in malignant patients. Our track consists of completing the recruitment in the first part of the study. In addition, we saw during the March month that the recruitment in phase 1b, the study in severe malaria, which then has a room in Kenya and Zambia, is completed. And that opens up opportunities for us to work further with that strategy and see how we move forward with our collaboration partners towards the next step in that development. And also, I think we have seen that our portfolio renders interest outside of the typical spheres where we have, for example, participated. I got the opportunity to participate in a global roundtable. There is a number of important diseases, tuberculosis, malaria and HIV, and technical innovation in this area, which the world was divided by Global Fund and Swedish UD. These are some highlights, but as I said, it was a very successful quarter in a very good way.

Upplever du att intresset kring er forskning också ökar- om man ser mot bakgrund av det som sker nu i USA- med att man drar tillbaks finansiering för olika projekt? Jag tänker framförallt malaria då kanske. Och HIV finns ju där också. Men ser du att det ger ringar på vatten för er del- att det är större intresse för er forskning inom området?